​
​

Akari Therapeutics Stock (NASDAQ:AKTX)

ForecastOwnershipFinancialsChart
Akari Therapeutics by TradingView

Previous Close

$2.25

52W Range

$1.08 - $4.40

50D Avg

$2.76

200D Avg

$2.56

Market Cap

$25.26M

Avg Vol (3M)

$16.54K

Beta

0.95

Div Yield

-

AKTX Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

6

IPO Date

Jan 06, 2014

Website

AKTX Performance

AKTX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-16.81M$-23.09M$-17.21M
Net Income$-10.01M$-6.97M$-17.61M
EBITDA$-16.80M$-28.52M$-17.02M
Basic EPS$-2.04$-2.23$-8.20
Diluted EPS$-2.04$-2.23$-8.20

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q4 17Mar 21, 18 | 2:56 PM

Peer Comparison

TickerCompany
SLNOSoleno Therapeutics, Inc.
MGTADianthus Therapeutics, Inc.
ONCROncorus, Inc.
AXLAAxcella Health Inc.
PULMPulmatrix, Inc.
HSTOHistogen Inc.
CAPRCapricor Therapeutics, Inc.
DFFNCervoMed Inc.
SCPSScopus BioPharma Inc.
LABPLandos Biopharma, Inc.
PCSAProcessa Pharmaceuticals, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
SLRXSalarius Pharmaceuticals, Inc.